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Verapamil is a calcium channel blocker drug which reduces
heart rhythm and blood pressure in high blood pressure patient.
The steady state of this drug has to be continually controlled
to obtain optimal efficacy. In addition, patient compliance
needs to be considered. Therefore, controlled release tablet of
verapamil hydrochloride was essentially developed using hy-
drophilic matrix polymer, namely hydroxypropylmethyl
cellulose (HPMC) and sodium alginate, and compared to mar-
keted product [1]. HPMC, a pH-independent polymer, hydrates
to form a gel layer at the surface of the tablet to sustain the
drug release. Sodium alginate, a pH-dependent gelling polymer,
converts to insoluble alginic acid after exposure to acidic con-
dition in stomach.The development of verapamil hydrochloride
controlled release tablet was to vary the amount of HPMC and
sodium alginate. Alteration of the type and quantity of excipi-
ents were included. Tablets were prepared by wet granulation
method. Physical tests were evaluated on tablet such as ap-
pearance, thickness, hardness and weight variation. In
dissolution test, USP monograph was followed using USP ap-
paratus II (paddle). UV spectrophotometer was used to measure
the amount of drug release [2], and then f1, f2 values were
calculated. In assay study, high-pressure liquid chromatogra-
phy was performed.
The results showed that all formulations obviously passed
the physical tests. The type and amount of polymer signifi-
cantly affected the release of drug. For the effect of the variation
in type and amount of rate controlling agents, change in amount
of sodium alginate slightly affected the release of the drug while
change in amount of HPMC had a great impact because the
forming of gel layer at early stage (pH 1.2) created barrier to
control the drug release whereas at buffer stage (pH 6.8), sodium
alginate swelled and caused a synergistic control release effect
(Fig. 1a). For other excipients, decrease in the amount of mi-
crocrystalline cellulose, used as a disintegrant and magnesium
stearate, used as a lubricant could reduce tablet disintegra-
tion. Finally, povidone K30 as a binder agent could increase
granule compaction but with amount limitation. Formula-
tion with accepted range of drug release in USP monograph
was satisfactorily obtained and similar to themarketed product.
This formulation contained 2.67% of HPMC and 11.33% of
sodium alginate.The f1 and f2 values were 13.30 and 61.49, re-
spectively (Fig. 1b).
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Fig. 1 – Gel layer forming of tablet in acid and buffer condition. (a) Dissolution profile of the selected formulations prepared
with small scale and large scale production: HPMC:Sodium alginate = 2.67:11.33 compared to marketed product (b).
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